DUBLIN–(BUSINESS WIRE)–The “Medical Device CRO Market: Industry Trends and Global Forecasts, Till 2035 – Distribution by Target Therapeutic Area, Scale of OperationDUBLIN–(BUSINESS WIRE)–The “Medical Device CRO Market: Industry Trends and Global Forecasts, Till 2035 – Distribution by Target Therapeutic Area, Scale of Operation

Navigating the $19.3 Billion Medical Device CRO Market, 2025-2035: Mergers and Acquisitions Boost Geographical Consolidation – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Medical Device CRO Market: Industry Trends and Global Forecasts, Till 2035 – Distribution by Target Therapeutic Area, Scale of Operation, Device Class, Type of Clinical Service Offered, Type of Preclinical Service Offered and Key Geographies” has been added to ResearchAndMarkets.com’s offering.

The global medical device CRO market is projected to grow from USD 13.3 billion in the current year to USD 19.3 billion by 2035, driven by a significant CAGR during the forecast period. This growth is largely fueled by the increasing elderly population and the prevalence of chronic illnesses, sparking a demand for innovative medical devices. Since 2020, the USFDA has approved approximately 105 medical devices, with over 35 gaining approval each year. However, the industry faces hurdles, including a complex and resource-demanding product development phase, enhanced by regulatory mandates ensuring medical devices’ safety, which complicate operations for industry leaders.

To navigate these challenges, medical device developers increasingly outsource research activities to specialized CROs, which excel in handling clinical studies, regulatory demands, and safety compliance. These organizations facilitate the transition of innovative concepts to market, efficiently managing the product development lifecycle. The rapid integration of advanced technologies and tools, like risk monitoring systems and cloud computing, is reshaping the medical device landscape, forecasting significant growth for the CRO market in the coming decade.

Key insights from the report reveal that over 590 CROs claim competency in offering diverse research and analytical services for medical devices. The market is notably fragmented, with various players across different regions providing services for a range of device classes. CROs are continuously enhancing their capabilities to better their service offerings, evident in strategic mergers and acquisitions, where 53% target geographical consolidation. Over 14,000 trials involving approximately 4.6 million patients with various conditions are registered worldwide to assess medical devices’ efficacy and accuracy. The market’s steady growth is expected, propelled by stakeholders’ ongoing efforts.

The market segmentation reveals that clinical operations currently command the largest share. Notably, the clinical services sector remains dominant due to rising clinical trials on medical devices. Meanwhile, Class II devices are poised as the fastest-growing segment. In preclinical services, biocompatibility testing emerges as the fastest-growing type, though sterility and microbial testing hold a significant market share. CNS disorders dominate the therapeutic area segment, reflecting a substantial part of the device CRO market. Geographically, North America leads the charge with the largest market share, though other regions are expected to grow at higher CAGRs over the years.

Prominent players within this space include Avania, Charles River Laboratories, CROMSOURCE, CSSi LifeSciences, Eurofins Medical Testing, IQVIA, Medpace, NAMSA, Qserve Group, and WuXi AppTec. The research report, bolstered by conversations with various industry stakeholders, investigates several factors, including market sizing, competitive benchmarking, regulatory landscapes, and clinical trials analysis.

The study addresses critical questions like the number of active companies, leading market players, influencers on market evolution, and market size forecasts. It offers a comprehensive market overview, including SWOT analysis, to guide stakeholders in making informed decisions. Additional benefits include complimentary PPT insights, Excel data packs, and content customization, coupled with report walkthrough sessions for detailed understanding, ensuring stakeholders are well-equipped to navigate and excel in the medical device CRO market.

Key Topics Covered

Section I: Report Overview

1. Preface

2. Research Methodology

3. Market Dynamics

4. Macro-Economic Indicators

Section II: Qualitative Insights

5. Executive Summary

6. Introduction

7. Regulatory and Reimbursement Landscape for Medical Devices

Section III: Competitive Landscape

8. Medical Device Preclinical CROs: Market Landscape

9. Medical Device Clinical CROs: Market Landscape

10. Brand Positioning Analysis: Preclinical Medical Device CROs

11. Competitive Benchmarking: Clinical CROs

Section IV: Company Profiles

12. Company Profiles

Section V: Market Trends

13. Mergers and Acquisitions

14. Clinical Trial Analysis

15. Future Trends and Opportunities

Section VI: Market Forecast and Opportunity Analysis

16. SWOT Analysis

17. Global Medical Device CRO Market

18. Medical Device CRO Market, by Class of Medical Device

19. Medical Device CRO Market, by Type of Medical Device

20. Medical Device CRO Market, by Scale of Operation

21. Medical Device CRO Market, by Type of Preclinical Service Offered

22. Medical Device CRO Market, by Type of Clinical Service Offered

23. Medical Device CRO Market, by Company Size

24. Medical Device CRO Market, by Type of Original Equipment Manufacturer

25. Medical Device CRO Market, by Target Indication

26. Medical Device CRO Market, by Geographical Regions

27. Medical Device CRO Market, by Leading Players

Section VII: Case Study

28. Medical Device Developer and CRO Relationships: Key Value Drivers and Performance Indicators

29. Total Cost of Ownership for Medical Devices CROs

30. Case Study: List of Additional Medical Device CROs

Section VIII: Other Exclusive Insights

31. Conclusion

32. Executive Insights

Section IX: Appendices

33. Appendix I: Tabulated Data

34. Appendix II: List of Additional Medical Device Clinical CROs

35. Appendix III: List of Companies and Organizations

A selection of companies mentioned in this report includes, but is not limited to:

  • 1MED
  • 4Clinics
  • 4Pharma
  • A+ Science
  • Abiogenesis Clinpharm
  • Abond CRO
  • Absorption Systems
  • ABX-CRO
  • Acceliant
  • Accell Clinical Research
  • AccelLAB
  • Accelovance
  • Accredited Consultants
  • AccuLab Life Sciences
  • Accuprec Research Labs
  • Accutest Research Laboratories
  • Acorn Regulatory
  • Acrapack
  • acromion
  • aCROss Medical
  • ACT FARMA CRO
  • Activa Cro
  • ADAX International
  • Advanced Drug Development Services
  • Advanced Medical Research
  • Advena
  • Affinity Bio Partners
  • Afortiori Development
  • Afra Pharma Consultant
  • Aginko Research
  • AICROS
  • CETERA
  • AIX Scientifics
  • AJW Technology Consultants
  • AKRN
  • Al Tamimi & Company
  • Alera Labs
  • Alira Health
  • Allied Clinical Management
  • Altair Clinical
  • Altasciences
  • Altiora
  • AlvaMed
  • Amarex
  • American Preclinical Services (Acquired by NAMSA)
  • and many, many more!

For more information about this report visit https://www.researchandmarkets.com/r/ckgb1w

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Market Opportunity
Cronos Logo
Cronos Price(CRO)
$0.09529
$0.09529$0.09529
-1.98%
USD
Cronos (CRO) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Pi Network Implements Protocol v23 on Testnet, Boosts Pi Coin Value

Pi Network Implements Protocol v23 on Testnet, Boosts Pi Coin Value

TLDR Pi Network has successfully deployed Protocol v23 on its testnet, marking a key milestone in its blockchain development. Following the testnet upgrade, Pi Coin experienced a 1.51% price increase, along with a 40.4% rise in market value. The testnet validation confirmed the success of Protocol v23, processing up to 1,000 transactions per block without [...] The post Pi Network Implements Protocol v23 on Testnet, Boosts Pi Coin Value appeared first on Blockonomi.
Share
Blockonomi2025/09/20 00:28
Robert W. Baird & Co. Discloses Core AI Design Parameters and Launches Public Testing of Baird NEUROFORGE™ Equity AI

Robert W. Baird & Co. Discloses Core AI Design Parameters and Launches Public Testing of Baird NEUROFORGE™ Equity AI

New York, United States (PinionNewswire) — Robert W. Baird & Co. (“Baird”) today announced the public disclosure of selected core system design parameters of its
Share
AI Journal2025/12/23 02:16
BlackRock boosts AI and US equity exposure in $185 billion models

BlackRock boosts AI and US equity exposure in $185 billion models

The post BlackRock boosts AI and US equity exposure in $185 billion models appeared on BitcoinEthereumNews.com. BlackRock is steering $185 billion worth of model portfolios deeper into US stocks and artificial intelligence. The decision came this week as the asset manager adjusted its entire model suite, increasing its equity allocation and dumping exposure to international developed markets. The firm now sits 2% overweight on stocks, after money moved between several of its biggest exchange-traded funds. This wasn’t a slow shuffle. Billions flowed across multiple ETFs on Tuesday as BlackRock executed the realignment. The iShares S&P 100 ETF (OEF) alone brought in $3.4 billion, the largest single-day haul in its history. The iShares Core S&P 500 ETF (IVV) collected $2.3 billion, while the iShares US Equity Factor Rotation Active ETF (DYNF) added nearly $2 billion. The rebalancing triggered swift inflows and outflows that realigned investor exposure on the back of performance data and macroeconomic outlooks. BlackRock raises equities on strong US earnings The model updates come as BlackRock backs the rally in American stocks, fueled by strong earnings and optimism around rate cuts. In an investment letter obtained by Bloomberg, the firm said US companies have delivered 11% earnings growth since the third quarter of 2024. Meanwhile, earnings across other developed markets barely touched 2%. That gap helped push the decision to drop international holdings in favor of American ones. Michael Gates, lead portfolio manager for BlackRock’s Target Allocation ETF model portfolio suite, said the US market is the only one showing consistency in sales growth, profit delivery, and revisions in analyst forecasts. “The US equity market continues to stand alone in terms of earnings delivery, sales growth and sustainable trends in analyst estimates and revisions,” Michael wrote. He added that non-US developed markets lagged far behind, especially when it came to sales. This week’s changes reflect that position. The move was made ahead of the Federal…
Share
BitcoinEthereumNews2025/09/18 01:44